AbCellera entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology. Under the agreement, Incyte has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive clinical and regulatory milestone payments and royalties on sales of products. “We are excited to partner with Incyte, which has a track record of developing first-in-class medicin...